Do statins protect against the development of Clostridium difficile - associated diarrhoea?

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 8, 2013, Pages 1889-1893

  Nseir, William ^a,b   Bishara, Jihad ^c,d   Mograbi, Julnar ^a   Mahamid, Mahmud ^a   Khalaila, Wissam ^a   Taha, Muhammad ^a   Farah, Raymond ^b,e  

^a Bar Ilan Faculty of Medicine   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e Rebecca Sieff Government Hospital   (Israel)

Author keywords

CDI; Predictors; Risk factors; Simvastatin

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL TOXIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEPRAZOLE; PROTON PUMP INHIBITOR; SIMVASTATIN;

ABDOMINAL SURGERY; ADULT; AGE; AGED; ANTIBIOTIC THERAPY; ARTICLE; CASE CONTROL STUDY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; CONTROLLED STUDY; DRUG USE; FECES ANALYSIS; FEMALE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; NONHUMAN; RETROSPECTIVE STUDY; SCORING SYSTEM; SEX DIFFERENCE; STOMACH PROTECTION;

CDI; PREDICTORS; RISK FACTORS; SIMVASTATIN;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; FECES; FEMALE; HOSPITALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 84880741341     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt101     Document Type: Article

References (41)

1. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257-62.
2. Dallal RM, Harbrecht BG, Boujoukas AJ et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235: 363-72.
3. Bignardi GE. Risk for Clostridium difficile infection. J Hosp Infect 1998; 40: 1-15.
4. Johnson S, Gerding DN. Clostridium difficile infection. Clin Infect Dis 1998; 26: 1027-34.
5. Barbut F, Petit JC. Epidemiology of Clostridium difficile-associated diarrhea. Clin Microbiol Infect 2001; 7: 405-41.
6. Thorpe CM, Gorbach SL. Update on Clostridium difficile. Curr Treat Options Gastroenterol 2006; 9: 265-71.
7. Al-Tureihi FI, Hassoun A, Wolf-Klein G et al. Length of stay and proton pump inhibitors: key factors in Clostridium difficile-associated diarrhea in nursing home patients. J Am Med Dir Assoc 2005; 6: 105-8.
8. Spencer RC. Clinical impact and associated costs of Clostridium difficile-associated diarrhea. J Antimicrob Chemother 1998; 41 Suppl C: 5-12.
9. Kyne I, Hamel MB, Polavaram R et al. Health care costs and mortality associated with nosocomial diarrhea. Clin Infect Dis 2002; 34: 346-53.
10. Al-Eidan FA, McElnay JC, Scott MG et al. Clostridium difficile-associated diarrhea in hospitalized patients. J Clin Pharm Ther 2000; 25: 101-9.
11. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systemic review. J Antimicrob Chemother 2003; 51: 1339-50.
12. Peled N, Pitlik S, Samra Z et al. Predicting Clostridium difficile toxin in hospitalized patients with antibiotic-associated diarrhea. Infect Control Hosp Epidemiol 2007; 28: 377-81.
13. Dial S, Delaney JA, Barkun AN et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated diarrhea. JAMA 2005; 21: 2989-95.
14. Yearsley KA, Gilby LJ, Ramadas AV et al. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhea. Aliment Pharmacol Ther 2006; 24: 613-9.
15. Jain MK, Ridker PM. Anti-inflammatory of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4: 977-87.
16. Nseir W, Khateeb J, Tatour I et al. Long-term statin therapy affects the severity of chronic gastritis. Helicobacter 2010; 15: 510-5.
17. Nseir W, Mograbi J, Abu-Elheja O et al. The impact of long-term versus short-term statin use on the mortality of bacteraemic patients. Infection 2012; 40: 41-8.
18. Motzkus-Feaganus CA, Pakyz A, Polk R et al. Statin use and the risk of Clostridium difficile in academic medical centers. Gut 2012; 61: 1538-42.
19. Lee SJ, Qin H, Benveniste EN. Simvastatin inhibits IFN-g-induced CD40 gene expression by suppressing STAT-1a. J Leukoc Biol 2007; 82: 436-47.
20. Naggie S, Miller BA, Zuzak KB et al. A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med 2011; 124: 276-7.
21. Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 2012; 18 Suppl 6: 21-7.
22. Thibault A, Miller MA, Gaese C. Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak. Infect Control Hosp Epidemiol 1991; 12: 345-8.
23. Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004; 109 Suppl II: II-42-8.
24. Sakabe K, Fukuda N, Wakayama K et al. Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia. Am J Cardiol 2004; 94: 497-500.
25. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
26. Sparrow CP, Burton CA, Hernandez M et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21: 115-21.
27. Blanco-Colio LM, Munoz-Gracia B, Martin-Vetura JL et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes. Circulation 2003; 108: 1506-13.
28. Hakamada-Taguchi R, Uehara Y, Kuribayashi K et al. Inhibition of hydroxymethylglutaryl coenzyme A reductase reduces Th1 development and promotes Th2 development. Circ Res 2003; 93: 948-56.
29. Blanco-Colio LM, Villa A, Ortego M et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002; 161: 17-26.
30. Jank T, Giesmann T, Aktories K. Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology 2007; 17: 15R-22R.
31. McGuire T, Dobesh P, Klepser D et al. Clinically important interaction between statin drugs and Clostridium difficile toxin? Med Hypotheses 2009; 73: 1045-7.
32. Pruefer D, Makowski J, Schmell M et al. Simvastatin inhibits inflammatory properties of Staphylococcus aureus a-toxin. Circulation 2002; 106: 2104-10.
33. Liappis AP, Kan VL, Rochester CG et al. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001; 33: 1352-7.
34. Masadeh M, Mhaidat N, Alzoubi K et al. Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin. Am Clin Microbiol Antimicrob 2012; 11: 13.
35. Kruger P, Fitzsimmons K, Cook D et al. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2006; 32: 75-9.
36. Tleyjeh IM, Kashour T, Hakim FA et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009; 169: 1658-67.
37. Nseir W, Diab H, Mahamid M et al. Randomized clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate - a placebo-controlled study. Aliment Pharmacol Ther 2012; 36: 231-8.
38. Kothe H, Dalhoff H, Rupp J et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 2000; 101: 1760-3.
39. Borody TJ, Warren EF, Leis SM et al. Bacteriotherapy using fecal flora: toying with human motions. Clin Gastroenterol 2004; 38: 475-83.
40. Hopkins MJ, Macfarlane GT. Changes in predominant bacterial population in human feces with age and with Clostridium difficile infection. J Med Microbiol 2002; 51: 448-54.
41. Manges AR, Labbe A, Loo VG et al. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridium difficile-associated disease. J Infect Dis 2010; 202: 1877-84.